BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 9763557)

  • 21. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
    Roy A; Bradburn M; Moorman AV; Burrett J; Love S; Kinsey SE; Mitchell C; Vora A; Eden T; Lilleyman JS; Hann I; Saha V;
    Br J Haematol; 2005 Apr; 129(1):35-44. PubMed ID: 15801953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.
    Lauten M; Stanulla M; Zimmermann M; Welte K; Riehm H; Schrappe M
    Klin Padiatr; 2001; 213(4):169-74. PubMed ID: 11528550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia.
    Wingard JR; Piantadosi S; Santos GW; Saral R; Vriesendorp HM; Yeager AM; Burns WH; Ambinder RF; Braine HG; Elfenbein G
    J Clin Oncol; 1990 May; 8(5):820-30. PubMed ID: 2332770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: a 15-year experience.
    Jamieson CH; Amylon MD; Wong RM; Blume KG
    Exp Hematol; 2003 Oct; 31(10):981-6. PubMed ID: 14550815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
    Yetgin S; Cetin M
    Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.
    Schrappe M; Reiter A; Zimmermann M; Harbott J; Ludwig WD; Henze G; Gadner H; Odenwald E; Riehm H
    Leukemia; 2000 Dec; 14(12):2205-22. PubMed ID: 11187912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90.
    Neth O; Seidemann K; Jansen P; Mann G; Tiemann M; Ludwig WD; Riehm H; Reiter A
    Med Pediatr Oncol; 2000 Jul; 35(1):20-7. PubMed ID: 10881003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
    Schrappe M; Reiter A; Ludwig WD; Harbott J; Zimmermann M; Hiddemann W; Niemeyer C; Henze G; Feldges A; Zintl F; Kornhuber B; Ritter J; Welte K; Gadner H; Riehm H
    Blood; 2000 Jun; 95(11):3310-22. PubMed ID: 10828010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
    Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
    Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
    Klimza MJ; Sońta-Jakimczyk DJ
    Wiad Lek; 2005; 58(11-12):622-5. PubMed ID: 16594471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.
    Stamati L; Avgeris M; Kosmidis H; Baka M; Anastasiou T; Piatopoulou D; Scorilas A; Gourgiotis D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2023-36. PubMed ID: 25982455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study.
    Biondi A; Schrappe M; De Lorenzo P; Castor A; Lucchini G; Gandemer V; Pieters R; Stary J; Escherich G; Campbell M; Li CK; Vora A; Aricò M; Röttgers S; Saha V; Valsecchi MG
    Lancet Oncol; 2012 Sep; 13(9):936-45. PubMed ID: 22898679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic bone marrow transplantation vs chemotherapy for children with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sharathkumar A; Saunders EF; Dror Y; Grant R; Greenberg M; Weitzman S; Chan H; Calderwood S; Freedman MH; Doyle J
    Bone Marrow Transplant; 2004 Jan; 33(1):39-45. PubMed ID: 14566329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.